April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Ocular Pharmacokinetics of P-321, a Novel Long-Acting Epithelial Sodium Channel Blocker
Author Affiliations & Notes
  • John H Ansede
    Parion Sciences, Durham, NC
  • William Thelin
    Parion Sciences, Durham, NC
  • Richard C Boucher
    University of North Carolina, Chapel Hill, NC
  • M. Ross Johnson
    Parion Sciences, Durham, NC
  • Pramod Terse
    National Institute of Health, Bethesda, MD
  • Katherine Warren
    Covance Laboratories, Madison, WI
  • Jose L Boyer
    Parion Sciences, Durham, NC
  • Footnotes
    Commercial Relationships John Ansede, Parion Sciences (E); William Thelin, Parion Sciences (E); Richard Boucher, Parion Sciences (C); M. Ross Johnson, Parion Sciences (E); Pramod Terse, None; Katherine Warren, None; Jose Boyer, Parion Sciences (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3693. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      John H Ansede, William Thelin, Richard C Boucher, M. Ross Johnson, Pramod Terse, Katherine Warren, Jose L Boyer; Ocular Pharmacokinetics of P-321, a Novel Long-Acting Epithelial Sodium Channel Blocker. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3693.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: P-321 is a potent epithelial sodium channel (ENaC) blocker that is being developed by Parion Sciences as a topical therapy for the treatment of dry eye. ENaC plays a key role in the regulation of tear fluid and is therefore an attractive target for the treatment of dry eye. To study the pharmacokinetics of P-321 in the eye, P-321 was administered via ocular instillation and drug concentrations in ocular tissues were measured following a single dose or during repeated administration over 14-days.

Methods: P-321 (0.1%) was administered via ocular instillation to Dutch Belted rabbits. Drug levels were measured in plasma, tears, and ocular tissues following a single administration and at different times during QID administration for 14 days. Following extraction, the concentration of P-321 was assayed by LC-MS/MS.

Results: P-321 is metabolically stable and therefore only the parent drug was monitored. Following single administration, P-321 elimination from tears was biphasic showing a rapid initial loss from tears followed by a long terminal elimination phase (t1/2 = 24 hr). Upon repeated administration, tear concentrations of P-321 increased and reached steady state levels by Day 6. P-321 was retained in the conjunctiva following single dose administration with palpebral drug concentration approximately five times higher than bulbar conjunctiva. After a single dose, conjunctiva concentrations of P-321 remained relatively constant for up to 48 hours and steady-state levels were achieved by Day 2 during 14 days of QID dosing. P-321 was only detected at sub nanomolar concentrations in aqueous humor five minutes post-dose. Aqueous humor concentrations increased slightly during multiple dose administration reaching steady state levels by Day 4. P-321 was detected in the cornea immediately following dose administration, however, no drug was detected thereafter or during 14-days of QID administration. P-321 was not detected in retina or lacrimal glands.

Conclusions: P-321 is a novel ocular hydrating agent capable of restoring normal tear volume in a dry eye animal model. The results presented in this study indicate that P-321 is well retained on the ocular surface of the eye (primarily in the tears and conjunctiva), providing the pharmacokinetic basis to explain its long duration of action. Furthermore, P-321 shows very little penetration or accumulation in other ocular tissues.

Keywords: 474 conjunctiva • 482 cornea: epithelium • 486 cornea: tears/tear film/dry eye  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×